Contineum Therapeutics Inc. has provided an update on its Phase 1b positron emission tomography $(PET.AU)$ trial of PIPE-791, an antagonist targeting the lysophosphatidic acid 1 (LPA1) receptor. The clinical-stage biopharmaceutical company, focusing on neuroscience, inflammation, and immunology therapies, has completed enrollment of healthy volunteers and progressive multiple sclerosis (PrMS) cohorts. The ongoing trial aims to assess the correlation between pharmacokinetics and LPA1 receptor occupancy in these groups, with screening and enrollment of idiopathic pulmonary fibrosis $(IPF.UK)$ patients still in progress. The company plans to present topline data from the fully enrolled cohorts in the third quarter of 2025.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.